HU9501717D0 - Monomeric insulin analog formulations - Google Patents

Monomeric insulin analog formulations

Info

Publication number
HU9501717D0
HU9501717D0 HU9501717A HU9501717A HU9501717D0 HU 9501717 D0 HU9501717 D0 HU 9501717D0 HU 9501717 A HU9501717 A HU 9501717A HU 9501717 A HU9501717 A HU 9501717A HU 9501717 D0 HU9501717 D0 HU 9501717D0
Authority
HU
Hungary
Prior art keywords
insulin analog
monomeric insulin
analog formulations
formulations
monomeric
Prior art date
Application number
HU9501717A
Other languages
English (en)
Other versions
HU218943B (hu
HUT71908A (en
Inventor
Felippis Michael Rosario De
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22989963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU9501717(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HU9501717D0 publication Critical patent/HU9501717D0/hu
Publication of HUT71908A publication Critical patent/HUT71908A/hu
Publication of HU218943B publication Critical patent/HU218943B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
HU9501717A 1994-06-16 1995-06-13 Inzulin-analóg-protamin komplexek, az azokat tartalmazó gyógyászati készítmények és eljárás ezek előállítására HU218943B (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/260,633 US5461031A (en) 1994-06-16 1994-06-16 Monomeric insulin analog formulations

Publications (3)

Publication Number Publication Date
HU9501717D0 true HU9501717D0 (en) 1995-08-28
HUT71908A HUT71908A (en) 1996-02-28
HU218943B HU218943B (hu) 2001-01-29

Family

ID=22989963

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9501717A HU218943B (hu) 1994-06-16 1995-06-13 Inzulin-analóg-protamin komplexek, az azokat tartalmazó gyógyászati készítmények és eljárás ezek előállítására

Country Status (37)

Country Link
US (3) US5461031A (hu)
JP (1) JP3812962B2 (hu)
KR (1) KR100386038B1 (hu)
CN (1) CN1145641C (hu)
AT (1) AT408611B (hu)
BE (1) BE1009409A5 (hu)
BR (1) BR9502797A (hu)
CA (1) CA2151564C (hu)
CH (2) CH689934A5 (hu)
CO (1) CO4410204A1 (hu)
CZ (1) CZ294556B6 (hu)
DE (1) DE19521753B4 (hu)
DK (1) DK176213B1 (hu)
ES (1) ES2091728B1 (hu)
FI (1) FI118208B (hu)
FR (1) FR2721215B1 (hu)
GB (1) GB2290294B (hu)
GR (1) GR1002494B (hu)
HU (1) HU218943B (hu)
IE (1) IE68852B1 (hu)
IL (1) IL114153A (hu)
IT (1) IT1276722B1 (hu)
LU (1) LU88627A1 (hu)
MY (1) MY116831A (hu)
NL (2) NL1000565C2 (hu)
NO (1) NO320808B1 (hu)
NZ (1) NZ272360A (hu)
PE (1) PE34496A1 (hu)
PL (1) PL183284B1 (hu)
PT (1) PT101723B (hu)
RO (1) RO115124B1 (hu)
SE (1) SE509295C2 (hu)
SI (1) SI9500199A (hu)
TW (1) TW347334B (hu)
UA (1) UA34468C2 (hu)
YU (1) YU39795A (hu)
ZA (1) ZA954941B (hu)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
EP1607086A1 (en) * 1993-01-29 2005-12-21 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
US5888477A (en) * 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
US6131567A (en) * 1993-01-29 2000-10-17 Aradigm Corporation Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
US6274549B1 (en) * 1995-06-30 2001-08-14 Novo Nordisk A/S Treatment of type 1 diabetes
ATE208208T1 (de) * 1996-06-20 2001-11-15 Novo Nordisk As Halogenid-enthaltende insulinzubereitungen
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
AU5749198A (en) * 1997-02-07 1998-08-26 Novo Nordisk A/S Crystallisation of proteins
ZA984697B (en) * 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
EP1283051B1 (en) * 1997-06-13 2006-06-14 Eli Lilly And Company Stable insulin formulations
EP1039920A4 (en) * 1997-10-24 2003-05-28 Lilly Co Eli INSULIN ANALOGS ACYLATED BY FATTY ACID
US6531448B1 (en) 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
US20040214747A1 (en) * 1999-01-06 2004-10-28 Dimarchi Richard Dennis Method for administering monomeric insulin
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
KR20030005204A (ko) * 2000-12-25 2003-01-17 가부시키가이샤 시세이도 교감신경 활성화 향료 조성물
HUP0500733A3 (en) * 2001-02-09 2010-01-28 Genentech Inc Crystallization of igf-1
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
MXPA04001560A (es) * 2001-08-28 2004-05-17 Lilly Co Eli Premezclas de glp-1 e insulina basal.
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7312192B2 (en) 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US20030068361A1 (en) * 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
US7179788B2 (en) * 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
AU2002346491A1 (en) * 2001-12-19 2003-07-09 Eli Lilly And Company Crystalline compositions for controlling blood glucose
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
AU2004247762B2 (en) 2003-06-17 2010-05-27 Sembiosys Genetics Inc. Methods for the production of insulin in plants
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
ES2328579T3 (es) * 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PL1740154T3 (pl) * 2004-03-12 2009-11-30 Biodel Inc Kompozycje insuliny o ulepszonym wchłanianiu
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
CA2580313C (en) 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
EP1789074A4 (en) * 2004-08-09 2009-08-12 Alios Biopharma Inc PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP2926828B1 (en) * 2004-10-05 2019-12-11 Novo Nordisk A/S A pharmaceutical formulation
JP4874989B2 (ja) 2004-11-22 2012-02-15 ノヴォ ノルディスク アー／エス 可溶性で安定なインスリン含有調合物
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) * 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
CN100371346C (zh) * 2005-12-14 2008-02-27 浙江大学 人工合成胰岛素模拟肽及其应用
ATE482977T1 (de) * 2006-02-27 2010-10-15 Novo Nordisk As Insulinderivate
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
CN101062948B (zh) * 2006-04-29 2010-05-12 上海生物泰生命科学研究有限公司 单体速效胰岛素及其制法和用途
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
EP2349279A4 (en) 2008-10-28 2013-12-25 Univ Leland Stanford Junior ALDEHYDE DEHYDROGENASE MODULATORS AND METHOD OF USE THEREOF
SG173112A1 (en) 2009-01-28 2011-08-29 Smartcells Inc Conjugate based systems for controlled drug delivery
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
US20110293562A1 (en) 2009-02-12 2011-12-01 Proyecto De Biomedicina Cima, S.L. Use of cardiotrophin-1 for the treatment of metabolic diseases
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
AU2010226243A1 (en) 2009-03-20 2011-09-22 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
HUP0900482A2 (en) * 2009-08-03 2011-03-28 Cera Med Kft Pharmaceutical formulation for oral administration
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
KR20140015266A (ko) * 2010-11-24 2014-02-06 듀렉트 코퍼레이션 생분해성 약물 전달 조성물
UY33872A (es) 2011-01-20 2012-08-31 Zealand Pharma As Uso de análogos de glucagón acilados
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
CA2890048C (en) 2012-12-03 2022-05-03 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
CN105358531B (zh) 2013-03-14 2017-11-14 利兰-斯坦福大学初级学院的董事会 线粒体醛脱氢酶‑2调节剂和其使用方法
BR112016007176A2 (pt) 2013-10-04 2018-01-23 Merck Sharp & Dohme conjugado, composição, usos de um conjugado e de uma composição, e, método para tratar um indivíduo que tem diabete
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
WO2015104311A1 (en) * 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN106102763A (zh) 2014-01-13 2016-11-09 塞尔玛琳糖尿病有限责任公司 速效胰岛素制剂和药物递送系统
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
WO2017163159A1 (en) 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
TWI762706B (zh) 2017-08-24 2022-05-01 丹麥商諾佛 儂迪克股份有限公司 Glp-1組成物及其用途
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
EP3727424A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN RELEASE
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations
PE20230457A1 (es) 2020-03-31 2023-03-10 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK119785D0 (da) * 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
IE62879B1 (en) * 1987-02-25 1995-03-08 Novo Nordisk As Novel insulin derivatives
DE3717370A1 (de) * 1987-05-22 1988-12-01 Hoechst Ag Mischkristalle aus insulin und insulinderivaten, verfahren zur herstellung dieser mischkristalle, diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
AU616205B2 (en) * 1988-07-20 1991-10-24 Novo Nordisk A/S Human insulin analogs and preparations containing them
KR910700262A (ko) * 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
NZ232375A (en) * 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
ES2130428T3 (es) * 1993-06-21 1999-07-01 Novo Nordisk As Cristales de insulina asp-b28.
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
GR1002494B (el) 1996-12-12
PL183284B1 (pl) 2002-06-28
JPH083064A (ja) 1996-01-09
MY116831A (en) 2004-04-30
HU218943B (hu) 2001-01-29
DK176213B1 (da) 2007-02-12
CA2151564C (en) 2003-02-11
FR2721215A1 (fr) 1995-12-22
DE19521753A1 (de) 1995-12-21
KR100386038B1 (ko) 2003-08-27
CZ294556B6 (cs) 2005-02-16
NL1000565A1 (nl) 1995-12-18
US5650486A (en) 1997-07-22
PT101723B (pt) 1997-02-28
ES2091728B1 (es) 1998-02-01
UA34468C2 (uk) 2001-03-15
IL114153A (en) 2000-09-28
AT408611B (de) 2002-01-25
DK67695A (da) 1995-12-17
NO952356L (no) 1995-12-18
US5461031A (en) 1995-10-24
SE509295C2 (sv) 1999-01-11
FR2721215B1 (fr) 1997-08-14
CH693019A5 (de) 2003-01-31
US5747642A (en) 1998-05-05
NL1004643A1 (nl) 1996-12-17
SE9502168D0 (sv) 1995-06-14
FI118208B (fi) 2007-08-31
FI952932A0 (fi) 1995-06-14
CZ154395A3 (en) 1996-02-14
PE34496A1 (es) 1996-10-01
JP3812962B2 (ja) 2006-08-23
RO115124B1 (ro) 1999-11-30
FI952932A (fi) 1995-12-17
GB2290294B (en) 1999-03-17
YU39795A (sh) 1998-05-15
DE19521753B4 (de) 2009-07-23
CN1145641C (zh) 2004-04-14
SI9500199A (en) 1996-02-29
PL309100A1 (en) 1995-12-27
BR9502797A (pt) 1996-03-12
IT1276722B1 (it) 1997-11-03
CA2151564A1 (en) 1995-12-17
BE1009409A5 (fr) 1997-03-04
SE9502168L (sv) 1995-12-17
GB9512105D0 (en) 1995-08-09
IL114153A0 (en) 1995-10-31
NZ272360A (en) 1997-02-24
TW347334B (en) 1998-12-11
ITMI951277A0 (it) 1995-06-14
ITMI951277A1 (it) 1996-12-14
CN1116629A (zh) 1996-02-14
ES2091728A1 (es) 1996-11-01
LU88627A1 (fr) 1996-02-01
HUT71908A (en) 1996-02-28
NO952356D0 (no) 1995-06-14
GB2290294A (en) 1995-12-20
CH689934A5 (de) 2000-02-15
IE950435A1 (en) 1995-12-27
NL1004643C2 (nl) 1997-02-12
PT101723A (pt) 1995-12-29
CO4410204A1 (es) 1997-01-09
NL1000565C2 (nl) 1996-12-03
IE68852B1 (en) 1996-07-24
ZA954941B (en) 1996-12-17
NO320808B1 (no) 2006-01-30
ATA101795A (de) 2001-06-15
KR960000923A (ko) 1996-01-25

Similar Documents

Publication Publication Date Title
GB2290294B (en) Monomeric insulin analog formulations
IL117696A (en) Monomeric insulin analog formulations
GB2291427B (en) Insulin analog formulations
HK1030747A1 (en) Stable insulin formulations
SI0884053T1 (en) Stable insulin formulations
GB9311030D0 (en) Pharmaceutical formulations
GB2327424B (en) Monomeric insulin analog formulations
AU2168295A (en) Monomeric insulin analog formulations
AU738101C (en) Monomeric insulin analog formulations
EG26644A (en) Preparations of monoclonal insulin analogs
AU694501C (en) Insulin analog formulations
AU731636C (en) Insulin analog formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations
GB9312344D0 (en) Pharmaceutical formulations
GB9304797D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9304799D0 (en) Pharmaceutical formulations
GB9304800D0 (en) Pharmaceutical formulations